Post-incarceration outcomes for individuals who continued methadone treatment while in Connecticut jails, 2014-2018.
Correctional settings
Methadone
Opioid overdose
Opioid use disorder
Reincarceration
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
received:
16
01
2021
revised:
28
06
2021
accepted:
03
07
2021
pubmed:
10
8
2021
medline:
9
2
2022
entrez:
9
8
2021
Statut:
ppublish
Résumé
To assess post-release outcomes associated with continuation of methadone treatment in correctional centers. This case-control study of the post-incarceration impact of pilot methadone programs operating in jails in New Haven and Bridgeport, Connecticut, USA was conducted in 2014-18. The study compared non-fatal overdose, fatal overdose, reincarceration, and resumption of methadone in the community experienced by 1564 eligible men, 660 (42.2 %) of whom continued treatment while incarcerated. Continuation of methadone was associated with a significant decrease in non-fatal overdose (OR:0.55; 95 % CI: 0.36, 0.85) and a greater likelihood of resuming methadone treatment in the community post-release (OR:2.56; 95 % CI: 2.07, 3.16). Time to resumption of methadone was shortened by treatment while time to non-fatal overdose was increased. Treatment while incarcerated resulted in a modest but not significant decrease in fatal overdoses and no difference in reincarceration between those who did and did not receive methadone. However, resumption of methadone after release did significantly reduce fatal overdoses (OR = 0.26, 95 % CI: 0.11, 0.62, p = 0.002). Improvements in post-release outcomes of non-fatal overdose and treatment reengagement emphasize the benefits of continuing medication-based treatment for opioid use disorder within the criminal justice system for those receiving it prior to being incarcerated.
Identifiants
pubmed: 34371235
pii: S0376-8716(21)00432-4
doi: 10.1016/j.drugalcdep.2021.108937
pmc: PMC8819627
mid: NIHMS1731089
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
108937Subventions
Organisme : Intramural CDC HHS
ID : NU1ROT000012
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Références
J Subst Abuse Treat. 2016 Nov;70:1-6
pubmed: 27692182
J Opioid Manag. 2009 Jul-Aug;5(4):219-27
pubmed: 19736902
Addiction. 2005 Jun;100(6):820-8
pubmed: 15918812
Lancet Psychiatry. 2015 May;2(5):422-430
pubmed: 26360286
Drug Alcohol Depend. 2006 Jun 28;83(2):122-9
pubmed: 16332415
JAMA Psychiatry. 2018 Apr 1;75(4):405-407
pubmed: 29450443
Lancet. 2015 Jul 25;386(9991):350-9
pubmed: 26028120
Addiction. 2008 Dec;103(12):2017-23
pubmed: 19469745
Addiction. 2008 Feb;103(2):251-5
pubmed: 18199304
Drug Alcohol Depend. 2018 Mar 1;184:57-63
pubmed: 29402680
J Addict Med. 2018 Mar/Apr;12(2):156-162
pubmed: 29341974
JAMA Netw Open. 2018 Jul 6;1(3):e180558
pubmed: 30646016
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
Subst Abus. 2012;33(1):19-29
pubmed: 22263710
Addiction. 2017 Aug;112(8):1432-1439
pubmed: 28319291
Subst Abuse Rehabil. 2016 Apr 27;7:27-40
pubmed: 27217808
Ann Intern Med. 2013 Nov 5;159(9):592-600
pubmed: 24189594
Am J Public Health. 2008 Dec;98(12):2278-84
pubmed: 18923131
Addiction. 2008 Aug;103(8):1333-42
pubmed: 18855822
Addiction. 2009 Jul;104(7):1233-40
pubmed: 19426291
Addiction. 2017 Aug;112(8):1408-1418
pubmed: 28160345
MMWR Morb Mortal Wkly Rep. 2015 Jul 10;64(26):719-25
pubmed: 26158353
Epidemiol Rev. 2018 Jun 1;40(1):121-133
pubmed: 29733373
Subst Abus. 2012;33(1):9-18
pubmed: 22263709
Drug Alcohol Depend. 2009 Jan 1;99(1-3):222-30
pubmed: 18930603
Crim Justice Behav. 2008;35(1):34-47
pubmed: 18612373